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Abstract 
Schizophrenia is a complex and unpredictable mental disorder which affects several domains 
of cognition and behaviour. It is a heterogeneous illness characterised by positive, negative, 
and cognitive symptoms, often accompanied by signs of depression. In this tutorial review, 
we discuss recent progress in understanding the target sites and mechanisms of action of 
second-generation antipsychotic drugs. Progress in identifying and defining target sites has 
been accelerated recently by advances in neuroscience, and newly developed agents that 
regulate signalling by the main excitatory neurotransmitters in the brain are surveyed. 
Examples of novel molecules for the treatment of schizophrenia in preclinical and clinical 
development and their industrial sponsors are highlighted. 
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Introduction 
Schizophrenia is one of the most mysterious disorders in psychiatry owing to its complex 
nature and unpredictable course. The very start of the disorder goes back to the early brain 
development stage and is known to result from genetic and environmental risk factors. The 
anatomical changes seen in the brains of patients diagnosed with schizophrenia include 
differences in volume and alterations of various regions of the brain such as the global, 
cortical, subcortical regions, white and grey matter. Its complex pathology includes 
abnormalities in the dopaminergic, serotonergic, glutamatergic and GABAergic (related to 
the function of γ-aminobutyric acid (GABA) neurotransmitter) systems. Such an 
heterogeneous (symptoms, course, response to treatment and outcome greatly vary with 
patients
1;2
) and complex mental disorder is challenging to cure, but recent progress in 
genomics, epidemiology and neuroscience
2
 have opened up new avenues for the design of 
suitable medications for the minimisation of schizophrenia effects and symptoms. A 
significant number of clinical trials now involve novel molecules for the treatment of 
schizophrenia. Some of the current (February 2018) clinical trials are listed in Table 1. 
Table 1. Some examples of industries/sponsors with molecules in development or clinical trials or 
approved for clinical use. In many cases more details can be found on the Clinical Trials website: 
http://www.clinicaltrials.gov/ 
Industry/ 
Sponsor 
Drug 
Type of 
drug/mechanism 
of action 
Targeted outcome Stage 
Eli Lilly 
(Generic since 
2011) 
Olanzapine 
Dopamine 
antagonist 
To reduce symptoms of 
schizophrenia, to treat acute 
exacerbations, and to treat 
early-onset schizophrenia 
Approved 
Generic  Risperidone 
Dopamine 
antagonist 
To reduce the overall 
symptoms of schizophrenia 
Approved 
Janssen 
Pharmaceutica. 
9-
hydroxyrisperid
one 
(Paliperidone) 
Dopamine 
antagonist and 
Serotonin 2A 
antagonist 
To treat schizoaffective 
disorder 
Approved 
Otsuka Aripiprazole Partial dopamine To treat acute exacerbations Approved 
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agonist of schizophrenia and for 
maintenance treatment 
(relapse prevention) 
ACADIA 
Pharmaceuticals 
Inc. 
Pimavanserin 
(Nuplazid) 
Selective inverse 
agonist of the 
serotonin 2A 
receptor 
To treat positive and 
negative symptoms 
Phase III 
Alkermes, Inc. 
Samidorphan 
and olanzapine 
(ALKS 3831) 
Mu opioid receptor 
antagonist and 
Dopamine 
antagonist 
To provide patients with 
the strong efficacy of 
olanzapine and a 
differentiated safety profile 
with favourable weight and 
metabolic properties 
Phase III 
Sumitomo 
Dainippon 
Pharma Co., 
Ltd. 
Blonanserin 
(DSP-5423P) 
Dopamine 2 
receptor 
antagonists; 
Serotonin 2A 
receptor antagonists 
To treat positive and 
negative symptoms 
Phase III 
Beth Israel 
Deaconess 
Medical Center 
Tiagabine 
GABA reuptake 
inhibitor 
To correct the brain deficits 
associated with the disease 
Phase III 
VA Office of 
Research and 
Development 
3-[2,4 
dimethoxybenzy
lidene] 
anabaseine 
(DMXB-A) 
Orally administered 
nicotinic 
cholinergic agonist 
To improve attention and 
other neuropsychological 
dysfunctions in 
schizophrenia, leading to 
improved psychosocial 
outcome 
Phase II 
Indiana 
University and 
Eli Lilly 
LY500307 
Selective estrogen 
receptor beta 
agonist 
To treat negative symptoms 
and cognitive impairment 
associated with 
schizophrenia 
Phase II 
Sunovion 
Pharmaceuticals 
Inc. 
SEP-363856 
Serotonin 1A 
receptor agonist; 
Trace amine-
associated receptor 
1 agonist 
To treat the positive and 
negative symptoms of 
schizophrenia, as well as 
hallucinations and 
delusions 
Phase II 
Avraham 
Reichenberg 
L-Carnosine (β-
alanyl-L-
histidine) 
Advanced glycation 
end-products 
production inhibitor 
To increase the 
performance of patients 
with schizophrenia on 
memory and learning 
training tasks 
Phase II 
Merck Sharp & 
Dohme Corp. 
MK-8189 Undisclosed To treat acute episode Phase II 
Massachusetts 
General 
Hospital 
Sodium 
nitroprusside 
Release of nitric 
oxide 
To treat positive and 
negative symptoms 
Phase II 
China Medical D-amino acid NMDA-enhancing To treat treatment-resistant Phase II 
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University 
Hospital 
oxidase inhibitor 
(DAAOI-2) 
agent Schizophrenia 
Central Institute 
of Mental 
Health, 
Mannheim 
Cannabidiol 
Cannabinoid 
receptors 1 and 2 
inverse agonist 
For maintenance treatment 
of schizophrenia 
Phase II 
Astellas Pharma 
Inc. 
ASP4345 Undisclosed 
To treat cognitive 
impairment associated with 
schizophrenia 
Phase I 
Otsuka 
Pharmaceutical 
Development & 
Commercializati
on, Inc. 
Brexpiprazole 
Dopamine 2 partial 
agonist 
To treat positive and 
negative symptoms 
Phase I 
Autifony 
Therapeutics 
Limited 
AUT00206 
Selective modulator 
Kv3 potassium 
channels 
To treat positive, negative 
and cognitive symptoms of 
schizophrenia 
Phase 1 
Brian Miller Siltuximab 
Chimeric 
monoclonal 
antibody 
Adjunct to antipsychotic 
medications 
Phase 1 
University of 
California, San 
Diego 
Memantine (3,5-
dimethyl-1-
adamantanamin
e) 
NMDA receptor 
antagonists 
To improve cognitive 
impairment and symptoms 
in schizophrenic patients 
Phase I 
University of 
Maryland 
L-
tetrahydropalma
tine 
Dopamine 1, 2, 3 
receptors antagonist 
Treatment of Schizophrenia 
with anti-inflammatory and 
antiprotozoal activity 
NCT0211
8610 
In 
developm
ent 
University of 
Colorado, 
Denver 
Levetiracetam 
(LEV: (S)-α-
ethyl-2-oxo-
pyrrolidine 
acetamide) 
Anticonvulsant and 
antiepileptic drug 
To reduce hippocampal 
activity in schizophrenia 
NCT0264
7437 In 
developm
ent 
 
The development of antipsychotics started in the 1950s with the approval of chlorpromazine 
and other ‘typical’ antipsychotics (such as haloperidol). Such a discovery allowed for the first 
time the de-institutionalisation of patients suffering from psychosis. A second generation of 
antipsychotics (also named as “atypical”), such as clozapine, became available in the late 
1980s. The large number of clinical trials currently recruiting and the continuing quest for 
finding drugs with novel mechanisms of action arise from the fact that both typical and 
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atypical antipsychotics, although having demonstrated some efficacy, do not treat all 
symptoms of the disease. Furthermore, the treatment of schizophrenia with antipsychotics is 
impaired by a number of side effects, such as motor side-effects, weight gain, and sedation. 
The treatment of the symptoms of schizophrenia is therefore of the utmost complexity, and is 
a task that can only be undertaken via interdisciplinary collaborations and concerted research 
efforts between chemists, biologists, and clinicians.  
In this tutorial review, we provide a brief overview of schizophrenia for non-specialist 
researchers that have interest in anti-schizophrenia chemical drug design or in the biological 
evaluation of such drug candidates. In order to introduce some emerging approaches for the 
treatment of schizophrenia, we survey the synthesis, mode of action, effectiveness and 
limitations of some of the most clinically used typical and atypical antipsychotics, and we 
highlight some of the current interests in antipsychotic design. We attempt to focus especially 
on their interactions with target sites, including glutamatergic signalling and inhibition of key 
transporters. Owing to the inter-individual variation in antipsychotic drug response, tailoring 
the design of drugs to target specific sites is likely to be a major part of future personalised 
medicine, which will include genomic and proteomic profiling of individuals.  
1. Schizophrenia in a nutshell 
1.1. Clinical signs and symptoms 
Schizophrenia is characterised by positive, negative, and cognitive symptoms; around 20% of 
diagnosed individuals have permanent and severe symptoms which cause disability, and more 
than 50% have non-persistent symptoms which follow a long-course.
2
  
Positive symptoms, also called psychotic symptoms, mainly occur during acute episodes of 
the disorder
1;3
 and include delusions, hallucinatory experiences, thought insertion or 
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withdrawal, and extraordinary behaviour. These symptoms tend to relapse and remit but some 
individuals report residual long-term symptoms.
2
 Antipsychotic drugs are used to help with 
positive symptoms and the outcome is usually positive.
4
 
Negative symptoms are more persistent than positive symptoms, and these can be divided 
into primary and secondary negative symptoms.
5
 The primary negative symptoms are likely 
to occur before the onset of the disorder and between psychotic episodes.
6
 Secondary 
negative symptoms occur along with the psychotic episodes or during depression.
5
 Negative 
symptoms include flat affect (decreased emotional response such as less movement and 
monotonic speech), alogia (poverty of speech), lack of volition, apathy and social withdrawal. 
Antipsychotic drugs have only minor effect on negative symptoms.
3
  
Cognitive symptoms are often seen before the onset of other symptoms of schizophrenia
1;7
 
and they are associated with poor performance of patients in a broad range of cognitive 
domains.
2;3
 These symptoms include thought disorder (core symptom of schizophrenia), 
thought blocking, derailment (patient cannot make a logical connection between words and 
sentences), poor attention, illogicality, clanging, neologism and echolalia (repeating of words, 
phrases or sounds).
4
 Between 20 and 30% of individuals diagnosed with schizophrenia do not 
show cognitive deficits.
3
 However, for individuals with cognitive symptoms, these tend to be 
chronic and often do not improve even if positive symptoms show good response to 
medications.
3;8
  
Other symptoms of schizophrenia include episodes of depression (observed in over 50% of 
cases),
3
 anxiety, hostility and aggression, and self-injury.
4
 The most frequent symptoms of 
acute schizophrenic disorder include lack of insight at 97%, auditory hallucinations at 74%, 
suspiciousness at 66%, voices speaking to the patient at 65% and thoughts spoken aloud at 
50%.
8
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1.2. Statistics 
Schizophrenia is known to begin in late adolescence and early adulthood, with typical age of 
onset for men - 23 years and for women - 28 years. However, the very start of the disorder 
goes back to the early brain development stage and is related to genetic and environmental 
risk factors. Genetic factors such as abnormalities of dopamine signalling and glutamatergic 
dysfunction are the core features of schizophrenia
2
 but these are also related to other mental 
illnesses such as autism and bipolar disorder.
8
 Environmental factors such as risk factors 
during pregnancy (maternal stress, infections, birth complications, growth retardation for 
example, immigration, birth in late winter, misuse of compounds with high content of 
tetrahydrocannabinol (cannabis), all contribute to schizophrenia, especially for individuals 
who are susceptible to the disorder.
2
  
Life expectancy is reduced by 15-20 years,
2
 where 40% of mortality account for suicide cases 
and 60% for health problems such as cardiorespiratory, infectious and musculoskeletal 
diseases.
3
 The duration of the illness is at least 6 months, with at least one month of severe 
symptoms known as ‘active-phase symptoms’. However, if the disorder is successfully 
treated with medications and psychological therapies, the duration of these severe symptoms 
can be reduced.
1
 Statistics show that only 11.5% of the people diagnosed with schizophrenia 
in the UK are working, which means that unemployment for schizophrenia is really high (ca. 
80 - 90%). The number of schizophrenic individuals in the UK who had experienced 
homelessness in their lifetime, reaches 32.8%.
9
  
1.3. Neurobiology of Schizophrenia 
Anatomical changes in the brains of people diagnosed with schizophrenia include differences 
in volume and alterations of not only white and grey matter, but also of different regions such 
as the global, cortical, subcortical regions (Figure 1).
1;10
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Figure 1.  Schematic representation of a cross section of a human brain. Reproduced with 
permission from reference.
11
 
Figure 2 summarises some of the most important changes observed in the brains of 
individuals diagnosed with schizophrenia.  
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Figure 2.  Summary of the different alterations found in the brains of patients diagnosed 
with schizophrenia. 
Global brain findings include a 2% reduced brain volume, and enlarged cerebral 
ventricles.
1;10
 Some studies show increases in ventricle size from 20 to 75% which are 
associated with schizophrenia. Ventricle enlargement supports the idea that schizophrenia is a 
progressive disorder because it has been found that this particular problem progresses with 
time if the individual does not follow the treatment. Patients with largest ventricles show 
most severe symptoms with small chances for positive outcomes.
10
 
Cortical findings include changes and alterations in the prefrontal cortex (PFC), temporal 
lobe and parietal lobe. The neuronal packing density, but not the number of neurons, is found 
to be higher in the entire frontal lobe and specifically in the dorsolateral prefrontal cortex 
(DLPFC). The DLPFC is of significant importance for investigations related to schizophrenia 
owing to its association with a number of symptoms and cognitive deficits. Analysis of the 
temporal lobe shows alterations in the medial temporal lobe, the superior temporal gyrus 
(STG) and the planum temporale. Positive symptoms of schizophrenia have been related to 
alterations of the temporal lobe and negative symptoms have been related more specifically 
to reductions in the left medial temporal lobe volume. Severity of auditory hallucinations and 
thought disorder are related to changes in the left anterior and left posterior STG. The medial 
temporal lobe includes the amygdala (responsible for emotions, and fear in general) and the 
parahippocampal gyrus (related to memory). A number of imaging studies and post-mortem 
investigations found that the volume of the medial temporal lobe of individuals diagnosed 
with schizophrenia is reduced.
10
 Volume decreases in amygdala-hippocampal complex are 
observed in both chronic and first-episode patients but these losses are also present in anxiety 
disorders, mood disorders and as a result of aging. Volume reductions in the parietal lobe, 
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particularly located in the inferior parietal lobe and supramarginal gyrus are associated to 
schizophrenia.
10
 
Subcortical findings include changes in the thalamus and basal ganglia of patients diagnosed 
with schizophrenia. The thalamus is responsible for the transmission of sensory impulses 
from various receptors throughout the body to the cerebral cortex and is smaller in size in 
patients with schizophrenia as compared to healthy subjects. When the thalamus is being 
subdivided, a decrease in the number of axons present in both the dorsomedial nucleus and 
the anteroventral nucleus is observed.
10
 When considering basal ganglia in patients diagnosed 
with schizophrenia, it has been found that there is an increase in its volume (with around 5 to 
25%)
1
 and this is considered to be a medication effect attributed to typical (first-generation) 
antipsychotic drugs.
10
 
The reduced brain volume in patients diagnosed with schizophrenia is related to a decrease in 
grey and white matter volume.
12;13
 Reductions in grey matter volume could be found in 
different regions of the brain and in different structures such as frontal and temporal areas, 
including the insular lobe, anterior cingulate gyrus, and superior temporal gyrus. The loss of 
grey matter volume results from cortical thinning and progresses with time. It is more severe 
in treated chronic patients than in medication-naive patients. White matter volume changes 
are also distributed across various brain regions and are mainly found in association fibres 
and tracts such as the arcuate and uncinate fasciculi.
12
 These findings support the theory of 
dysconnectivity in schizophrenia where symptoms, course and severity of the disorder are 
believed to result from the disconnections between different brain structures and their poor 
communication.
14;15
 Diffusion Tension Imaging (DTI) study, which is a special type of 
Magnetic Resonance Imaging (MRI) analysis related to white matter, confirmed white matter 
changes in the PFC (maldistribution of neurons), splenium, cingulum, temporoparietal and 
parieto-occipital regions, posterior capsule and medial temporal cortex.
10
 Reductions in white 
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matter volume in patients diagnosed with schizophrenia do not progress after the onset of the 
disorder and could even improve over time. One of the main reasons for white matter deficits 
in patients diagnosed with schizophrenia is believed to be the dysfunction of 
oligodendrocytes and these are responsible for the production of myelin which protects the 
nerve fibres in the central nervous system (CNS).
12
 
1.4. Neurochemistry of Schizophrenia 
Schizophrenia is a severe mental illness combining abnormalities of different 
neurotransmitters and receptors in the brains of patients diagnosed with the disorder. Its 
complex pathology includes alterations in the dopaminergic, serotonergic, glutamatergic and 
GABAergic (related to the function of γ-aminobutyric acid (GABA) neurotransmitter) 
systems. Dopamine hypothesis of schizophrenia is the oldest theory related to the disorder. 
Abnormalities of the dopamine receptors, dopamine synthesis and release, are observed in 
patients diagnosed with schizophrenia.
16
 Dopamine (Figure 3) is a neurotransmitter 
synthesised in neurones from extracellular tyrosine via dihydrophenylalanine.
17
  
 
Figure 3.  Molecular structures of dopamine (a), serotonin (b), L-glutamate (c), and 
GABA. (d). 
The molecule interacts with different postsynaptic receptors from D1 dopamine family 
(including D1 and D5 receptors) and D2 dopamine family (including D2, D3 and D4 
receptors).
18
 Dopamine is associated with a number of behaviours owing to its role in the 
control of motor activities, reward and pleasure, and thus contributes to cognition and 
volition.
1
 Schizophrenia could be partly characterised by prefrontal dopamine hypofunction 
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and subcortical dopamine hyperfunction.
19
 The prefrontal dopamine hypofunction (mainly in 
the PFC and anterior cingulate)
1
 is known to result in negative and cognitive symptoms of the 
disorder such as flat affect, lack of volition and thought disorder.
19;20
 The subcortical 
dopamine hyperactivity (mainly in Broca’s area, STG, cingulate gyrus and hippocampus)1 is 
thought to result in positive symptoms such as hallucinations and delusions. Evidence 
supporting this theory comes from the observation of higher dopamine levels correlating to 
greater positive symptoms and the response of patients to antipsychotic drugs.
19
 Positron 
emission tomography (PET) studies demonstrated reduced cerebral blood flow in the frontal 
cortex (hypofrontality)
1;19
 which is related to low cerebrospinal fluid dopamine metabolite 
levels, indicating dopamine hypofunction in the frontal region of the brains of patients 
diagnosed with schizophrenia.
19, 21
 Studies investigating striatum region in the brains of 
schizophrenic individuals or people at high risk for psychosis, found increased dopamine 
synthesis capacity, increased dopamine release and increased dopamine occupying the D2/3 
receptors.
16;19
 D2/3 dopamine receptor binding in the thalamus was also found to be reduced 
and the dopamine synthesis capacity in the temporal and limbic regions increased.
16, 22
 
Serotonergic systems are also involved in the neurochemistry of schizophrenia, interacting 
closely with the dopaminergic systems.
23
 Serotonin (or 5-hydroxytryptamine or 5-HT, Figure 
3), is a neurotransmitter synthesised from L-tryptophan, one of the essential amino acids. The 
5-HT systems are involved in mood balance and emotional processing, they are sensible to 
stress and therefore 5-HT dysfunction results in depression (a common symptom in 
schizophrenia).
20
 Post-mortem and in vivo molecular imaging studies of the serotonergic 
system show abnormal serotonin receptor function in patients diagnosed with 
schizophrenia.
24
 These studies reported reduction in 5HT2A receptors density (20 to 50%) and 
increase in 5-HT1A receptors density (20 to 90%).
20, 24
 The 5-HT2A receptors are of interest in 
schizophrenia as many of the newly developed (second-generation) antipsychotic drugs 
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display potent antagonism activity for this particular receptor subtype,
1;20
 but they also bind 
to other 5-HT receptors such as 5-HT1A, 5-HT2C and 5-HT7 receptors.
24
 
Glutamatergic systems also take part in the neuronal pathology of schizophrenia and it is 
believed that schizophrenia results from dysfunctional glutamate and glutamine 
neurotransmission which further damages other neuronal systems.
25
 Glutamate (Figure 32c) 
is the main excitatory transmitter in the brain and it is synthesised in neurones or glial cells 
from glutamine. Glutamatergic systems can influence dopamine function and either stimulate 
or inhibit dopamine release.
1;26
 Proton magnetic resonance spectroscopy (
1
H MRS) and 
single-photon emission computed tomography (SPECT) studies reported changes in the 
concentrations of glutamate, glutamine and a combination of both glutamate and glutamine 
(GLX) levels, in patients diagnosed with schizophrenia.
27
 These studies show increased GLX 
levels in the medial prefrontal cortex, thalamus, basal ganglia (BG), parietal region, occipital 
region and anterior cingulate.
28
 Glutamine concentrations are found to be elevated in the 
thalamus, anterior cingulate and medial prefrontal cortex, whilst Glutamate levels are found 
to be decreased in the thalamus but increased in the basal ganglia.
29
 The increased levels of 
glutamine and decreased levels of glutamate in the thalamus represent dysfunctional 
conversion of glutamine to glutamate in this region in the brains of patients diagnosed with 
schizophrenia. The increased concentrations of glutamate in GLX and basal ganglia are seen 
in patients before the first episode of psychosis and could be used as an indication of the 
schizophrenic syndrome.
30
 When patients are treated with antipsychotic drugs these levels 
decrease back to normal.
16
 N-methyl-D-aspartic acid (NMDA) receptor is one of the 
glutamate receptors and it is known to be involved in the mechanism of schizophrenia.
31
 It is 
an ionotropic receptor and it has a gated cation channel.
1
 NMDA receptors located on the 
dopaminergic neurons regulate extracellular dopamine. Reduction in the NMDA receptor 
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function in patients diagnosed with schizophrenia results in dysregulation of dopamine 
release – subcortical dopamine hyperfunction and prefrontal dopamine hypofunction.16  
GABA (Figure 3) is another important neurotransmitter involved in the neuronal pathology of 
schizophrenia.
32
 GABA is synthesised from glutamate by the enzyme glutamate 
decarboxylase. It is the main inhibitory transmitter in the brain and it binds to a range of 
postsynaptic receptors such as GABAA, GABAB and GABAC.
1
 Post-mortem and in vivo 
imaging studies demonstrated decreased GABA activity in the cortex and mesolimbic 
systems of patients diagnosed with schizophrenia.
1;20
 As GABA is the main inhibitory 
neurotransmitter in the brain, its decreased activity is believed to result in dopamine 
hyperactivity.
1;33 
1.5.Treatment 
The treatment of schizophrenia combines medications, psychological sessions and therapies, 
rehabilitation and social support. After the first episodes of psychosis, when treated with 
medications, around 20% of individuals report encouraging results, recovery and a positive 
outcome. Around 35% of individuals report symptoms that relapse and remit, with a good 
condition between episodes. Around 35% of individuals report chronic positive and negative 
symptoms, with a need for further treatment and psychological care. Around 10% of 
individuals report severe symptoms, with a need for a long-term treatment and special care.
3
 
Antipsychotic drugs have been used for many years and remain the mainstay for both the 
acute and long-term treatment of schizophrenia. This class of drugs could be divided in two 
major categories – first-generation antipsychotics (FGAs) (also called typical or 
conventional) and second-generation antipsychotics (SGAs) (also called atypical 
antipsychotic drugs).
2
 Here, we will explore the structures of clinically approved typical and 
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atypical antipsychotics, their modes of action, metabolism, effectiveness and limitations. We 
will also survey recent advances made in the chemical synthesis of antipsychotic drugs. 
2. Clinically-approved drugs 
2.1. Chlorpromazine 
Chlorpromazine (Figure 4) is the first antipsychotic drug developed and was discovered in 
1950 following a collaborative work between the Laboratoire d'Eutonologie at Boucicault 
Hospital (Paris, France) and the pharmaceutical company Rhône-Poulenc.
34
 It has been used 
in the treatment of psychoses, severe anxiety, psychotic aggression, resistant and severe 
hiccups, as well as for pre-anaesthetic conditioning.  
 
Figure 4.  Molecular structure of chlorpromazine. 
Chlorpromazine is a neuroleptic agent which is on the World Health Organisation (WHO)’s 
list of essential medicines.
35
 It also exhibits some sedative and antiemetic activities, and has 
led to the discovery of antidepressants.
36
 This drug had a tremendous impact on psychiatric 
patients, and its role was compared to the role of penicillin on infectious diseases. 
2.1.1. Synthesis 
Chlorpromazine is usually found as a salt: CPZ hydrochloride. Within its molecular structure, 
the nitrogen from the side chain can act both as a hydrogen bond donor and acceptor. Its 
synthesis was developed in 1950 by the French pharmaceutical company Rhône-Poulenc and 
CPZ went through clinical development with surgeons and psychiatrics in France in the early 
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1950’s. The first clinical trial was published in 1952 on the use of CPZ as a sedative agent 
before CPZ was approved for the treatment of many psychotic disorders, including 
schizophrenia a few years later.  
 
Scheme 1.  Synthesis of chlorpromazine from the original 1953 patent.37 
The synthesis of CPZ involves the condensation of the chlorophenothiazine cyclic compound 
with the tertiary aminoalkyl halide 3-dimethylamino-1-chloropropane in the presence of an 
acid-binding agent, such as sodium amide, using xylene as solvent. The 2-
chlorophenothiazine compound is prepared by cyclisation of the corresponding 2,5-dichloro-
N-phenylaniline with sulfur, with the use of iodine as catalyst.
37
 
2.1.2. Mode of action and metabolism 
Chlorpromazine is an antagonist on several dopamine receptors (D1, D2, D3, and D4). The 
particular blocking of D1 dopamine receptors diminishes neurotransmitter binding in the 
forebrain, and creates a feedback loop that causes the release of more dopamine after the first 
intake of the drug. Both the productive and unproductive symptoms are affected as a result. 
CPZ also strongly acts as an antagonist of serotonin receptors, 5-HT1 and 5-HT2,
38
 which is 
highly unusual for typical antipsychotics, and similar to atypical antipsychotics (with 
anxiolytic, anti-depressive, and anti-aggressive properties, attenuation of extra-pyramidal 
side-effects as well as some drawbacks such as weight gain, blood pressure fall, sedation and 
ejaculation difficulties).
39
 Chlorpromazine is one of the most potent agent at α-adregenic 
receptors, as reported for other antipsychotics with sedative properties, which accounts for 
sympatholytic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, 
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hypersalivation, incontinence and sexual dysfunction. This property coupled with its 
antagonist effect on histamine H1 receptors (accounting for sedation, antiemetic effect, 
vertigo, and weight gain) has led to the pharmaceutical development of CPZ as a anti-
histaminic agent.
40
 Other neurotransmitters are affected: epinephrine, norepinephrine, 
acetylcholine. This can lead to dry mouth, blurred vision, constipation, difficulty to urinate, 
loss of memory; however a positive impact on extrapyramidal side effects is reported. 
Chlorpromazine is metabolised by different pathways, including hydroxylation and 
conjugation with glucuronic acid, N-oxidation, S-oxidation, and dealkylation, all being part of 
the “first pass” metabolism. The highest concentrations of unconjugated metabolites are 
found in the lung and in the liver (almost 40% of the administered dose), which may lead to 
rare but severe idiosyncratic toxicity (hepatic injury).
41
 Cytochrome P450 plays a major role 
in its metabolism. Numerous metabolites are secreted (more than fifty have been reported), 
with various half-lives and pharmaceutical levels of activity.
42-44
  
2.1.3. Effectiveness 
Chlorpromazine was the first effective treatment available for schizophrenia to become 
available on the market in 1952 and is still one of the most commonly used antipsychotics 
owing to its low production cost.
45, 46
 However, the important weight gain is a major 
drawback, as well as the sedation effect.
47, 48
 In addition, CPZ exhibits the same levels of 
extrapyramidal side-effects (EPSEs) than most second-generation antipsychotics, which is 
unusual for a first-generation product.  
2.1.4. Limitations 
The administration of chlorpromazine leads to a number of side effects: Parkinsonism, 
jaundice, hypotension, convulsions, confusion, dermatitis, constipation, sedation.
49, 50
 The 
latter effect can be of benefit in the initial stages of treatment; some other side effects 
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disappear when the treatment is stopped and do not appear again when the treatment 
resumes.
51
  
2.2. Haloperidol 
Haloperidol (Figure 5) is a first-generation antipsychotic drug which has been in clinical use 
for more than fifty years and it has been involved in a huge number of studies all contributing 
to the development of neuroscience and playing an important role in psychiatry.
52;53 
  
Figure 5.  Molecular structure of haloperidol. 
Haloperidol is a strong neuroleptic agent which is included in the World Health 
Organisation’s list of essential medicines.53 It is proven to be effective for the treatment of 
positive symptoms associated with schizophrenia but it causes extrapyramidal side effects 
(for nearly 50% of all patients)
52
 and accentuates negative symptoms of the disorder.
54
 
Among the typical antipsychotic agents, haloperidol is the most widely prescribed drug with 
over 2.48 million prescriptions in 2008.
55
 Nowadays, it is also used for the treatment of 
hyperactivity, chorea associated with Huntington disease, obsessive-compulsive disorder, 
psychosis agitation associated with dementia, and rarely for nausea and vomiting induced by 
chemotherapy or surgery.
52
 There has been an ongoing comparison between typical and 
atypical drugs for years, and a recent study showed that patients treated with second-
generation antipsychotics continue their treatment for longer than subjects treated with 
haloperidol; moreover, atypical drugs seem to be more protective against recurrences when 
compared to haloperidol.
54
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2.2.1. Synthesis 
Haloperidol is part of the butyrophenone family (6-membered aromatic cycle conjugated with 
a ketone and an aliphatic chain). Within its molecular structure, the hydroxyl group acts as 
both a hydrogen bond acceptor and donor; the ketone oxygen and the piperidine nitrogen 
serve as two additional hydrogen bond acceptors. Due to these properties, haloperidol 
demonstrates high biological activity in humans.
52
 Its synthesis (Scheme 2) was developed in 
1958 by the Belgian company Janssen Pharmaceutica and it went through a clinical 
development by the psychiatric research team at the University of Liège where it was 
confirmed that it is effective for the treatment of different mental disorders such as chronic 
schizophrenia, mania and acute or chronic paranoid psychosis.
53
 
 
Scheme 2.  Synthesis of haloperidol adapted from reference52 
The synthesis of haloperidol involves a substitution reaction between a piperidine derivative 
and 4-chlorobutanoyl chloride in the presence of potassium iodide. The piperidine derivative 
is synthesised in four steps from an aromatic chloride compound. 4-chlorobutanoyl chloride 
is synthesised in one step from fluorobenzene.52 
2.2.2. Mode of action and metabolism 
Haloperidol demonstrates high affinity for dopamine D2 receptors
52;56
 particularly in the basal 
ganglia as the concentrations of D2 receptors in this region are high.
52
 It shows an 
approximately 100 fold higher affinity for the D2 receptor as compared to clozapine and also 
high residence time which both account for the occurrence of EPSEs.
52
 Haloperidol also 
demonstrates additional antagonist activity at serotonin 5-HT2A receptors, α1A and α1B 
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adrenergic receptors,
52
 and little affinity for muscarinic cholinergic and histamine receptors.
56
 
Two recent studies demonstrated the ability of haloperidol to bind to dopamine D3 
receptors.
57;58
 Zanatta et al. performed computer simulations at the molecular level for 
haloperidol and its binding patterns. They have demonstrated the important role of the axial 
orientation of the hydroxyl group within haloperidol’s structure which contributes to the 
favourable interaction with Tyr365 and Thr369 residues further increasing haloperidol’s 
binding to dopamine receptors.
57
  
Zhuravliova and co-workers showed that haloperidol induces neurotoxicity of neuronal cells 
as it interacts with the glutamate NMDA receptor which is known to be involved in 
excitotoxic neuronal cell death that occurs in many neurological disorders.
59
 
Haloperidol can be administered orally (haloperidol tablet or haloperidol lactate liquid), 
intravenously (haloperidol lactate) and as a long-acting intramuscular injection (haloperidol 
decanoate). It shows plasma protein binding of approximately 92% and plasma half-life of 24 
hours after it has been administered orally, 14 hours following an intravenous administration 
and 21 hours after it has been administered as an intramuscular injection.
52
 Haloperidol is 
metabolised by uridine 5’-diphospho-glucuronosyltransferases (UGTs) including UGT1A4, 
UGT1A9, UGT2B7
60
 and cytochrome P450 (CYP450) enzymes including 3A4,
61
 2D6 and 
1A2 enzymes.
52
 Nine different metabolites of haloperidol have been observed but the main 
one is known to be haloperidol glucuronide
52
 (Figure 6). 
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Figure 6.  Molecular structure of haloperidol glucuronide. 
When haloperidol is being metabolised only around 1% of the administered dose is detectable 
in urine. Smoking has been shown to increase the clearance of haloperidol by 44% whilst 
decreasing its serum concentrations by 70%.
52
 
2.2.3. Effectiveness 
Statistics show that 35 years after haloperidol was approved for the treatment of 
schizophrenia, 250 million people were treated with this agent. Since haloperidol is a strong 
dopamine D2 receptor antagonist, it is effective for the positive symptoms of schizophrenia 
such as delusions and hallucinatory experiences. Its discovery also contributed to the 
development of new theories related to schizophrenia and other mental disorders.
53
 
Nowadays, after the introduction of second-generation antipsychotics, haloperidol is rarely 
prescribed. Its strong potency for the dopamine D2 receptor may help with the positive 
symptoms of schizophrenia but it suffers from severe side effects.
52
 Newly developed 
antipsychotics drugs have different binding profiles and most of them offer better treatment 
for patients diagnosed with schizophrenia when compared to haloperidol.
54
 
2.2.4. Limitations 
Haloperidol is associated with a range of adverse events but the most common ones are 
EPSEs including dystonia, akathisia, dyskinesia and parkinsonism.
52
 Intravenous haloperidol 
can induce arrhythmias observed by electrocardiograms such as QT interval prolongation 
which can lead to incidents of irregular heart rhythms.
62;63
 Haloperidol is also associated with 
dysphoria which is characterised by depression, anxiety or agitation.
52
 It has been shown to 
be cytotoxic to neurons and to induce apoptosis in rodents by reducing cell survival 
signaling.
56;64
 Park et al. performed a study to assess the effects of antipsychotic agents on 
cell viability and autophagy (process of self-digestion by a cell) in rat primary neurons. 
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Haloperidol has been observed to decrease the viability of neurons and also to inhibit the 
autophagic process within the cell.
56
 
2.3.Clozapine 
Clozapine (Figure 7) is a second-generation antipsychotic drug which is the only 
antipsychotic agent available for treatment-resistant schizophrenia (TRS).
65;66 
 
Figure 7.  Molecular structure of clozapine. 
Clozapine was synthesised in the 1960s and it was the first atypical antipsychotic drug to be 
discovered. Typical drugs have the ability to treat positive symptoms without causing EPSEs. 
It is proved to be effective in treating positive and negative symptoms and some cognitive 
deficits (memory, verbal learning and fluency, and psychomotor speed). Clozapine was 
withdrawn in 1975 due to the risk of serious adverse effects (as 0.7% of patients in a study in 
Finland developed agranulocytosis and 50% of them died) but it was reapproved by the Food 
and Drug Administration (FDA) in 1989 due to its unique feature to be effective in TRS.
66
 
However, due to the ability of clozapine to cause agranulocytosis, FDA and all regulatory 
agencies worldwide recommend regular full blood counts (FBCs) for all patients on 
clozapine.
65;66
 Clozapine is only prescribed if the patient diagnosed with schizophrenia does 
not respond to two other antipsychotic agents, including an SGA.
67
 Typically clozapine is 
reserved only for the most severe cases of schizophrenia.
68
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2.3.1. Synthesis 
Clozapine is a tricyclic benzodiazepine derivative. It has a lone hydrogen bond donor and 
three hydrogen bond acceptors. The synthesis of clozapine (Scheme 3) was developed by 
Sandoz (nowadays Novartis).
66
 
 
Scheme 3.  Synthesis of clozapine 16 from main synthons.66 
Several routes have been developed for the synthesis of clozapine, however all focus on the 
synthesis of the key intermediate 8-chloro-5H-benzo[b,e][1,4]diazepin-11-(10H)-one core 
(Scheme 3, left). Two more steps are then needed to afford clozapine.
66
 
2.3.2. Mode of action and metabolism 
Clozapine binds to a range of receptors, including the dopaminergic (D1–D5), serotonergic (5-
HT2A, 5-HT2C, 5-HT6), cholinergic (M1, M2, M4), histaminergic (H1) and adrenergic (α1) 
receptors.
68
 It shows high affinity particularly for dopamine D2 receptors and serotonin 5-
HT2A receptors. It is found to be effective when it occupies 40-60% of striatal D2 receptors.
66
 
Clozapine does not saturate D2 receptors even if it is given at high doses as compared to 
risperidone.
69
 Among all SGAs, clozapine and olanzapine show the greatest affinity for 5-
HT2C and H1 receptors which accounts for their major adverse effect – weight gain.
65
 
Clozapine is also found to be a modest inhibitor of the sodium-coupled neutral amino acid 
transporter, which activates NMDA receptors by increasing the synaptic glycine levels.
70
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The recommended dose of clozapine is between 200 to 450 mg/day and this is divided into 
small doses which patients take throughout the day.
66
 Clozapine is 90-95% absorbed
66
 when 
taken orally and it is subject to first-pass metabolism which results in moderate 
bioavailability of 50-60%.
66;68
 It is metabolised by CYP450 enzymes and particularly by 1A2 
and 3A4 enzymes. The metabolism of clozapine results in 80% of the dose discharged as 
metabolites both in the urine (50%) and faeces (30%).
66
 Most of the metabolites of clozapine 
are inactive but N-desmethylclozapine (Figure 8) is an active metabolite which is believed to 
take part in the overall effectiveness of clozapine due to its activity on D2 and 5-HT2A 
receptors.
66;71 
 
Figure 8.  Molecular structure of N-desmethylclozapine. 
Cigarette smoke and other compounds which induce the activity of 1A2 enzyme, increase the 
clearance of clozapine (by up to 50%)
67
 and therefore smokers need higher doses of clozapine 
to maintain targeted plasma concentrations. Compounds such as ciprofloxacin inhibit 1A2 
enzyme resulting in a decrease in the rate of metabolism of clozapine.
66
 
2.3.3. Effectiveness 
Treatment with clozapine leads to reductions in the number of hospitalised patients. 
Significant improvement in the life of patients diagnosed with the disorder was demonstrated 
as well as a decrease in hospital costs and overall treatment expenses.
68
 Trials show that 50-
60% of patients diagnosed with schizophrenia in the UK respond to clozapine.
65
 Clozapine is 
also shown to reduce recurrent suicidal behaviour in schizophrenic patients by 88% compared 
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to other antipsychotic agents.
66
 Clozapine shows a range of advantages and these are listed in 
Table 2. 
Table 2: Clinical advantages of clozapine 
Clinical Advantages of Clozapine 
 The only antipsychotic agent available for TRS 
 Highly effective for the treatment of positive symptoms 
 More effective in reducing negative symptoms than the firstly approved typical 
antipsychotics 
 Significant improvement in the life of patients diagnosed with schizophrenia 
 Improved disorganised behaviour 
 Treatment with clozapine leads to reductions in the number of hospitalised patients 
 Decrease in hospital costs and overall treatment expenses 
 Efficacy on depression 
 Shown to reduce recurrent suicidal behaviour in subjects diagnosed with the 
disorder 
 No extrapyramidal side effects (EPSEs) 
 No tardive dyskinesia 
 No elevation in prolactin levels 
 Chance of relapse during clozapine therapy is less than with other antipsychotics 
 
2.3.4. Limitations 
Clozapine is associated with different adverse events including agranulocytosis (affects 0.8% 
of patients), sedation, elevation of liver enzymes (around 10%), constipation and 
hypersalivation (“wet pillow syndrome”).65;66 The increased risk of fatal agranulocytosis 
requires regular FBCs and strict monitoring protocol.
66;67
 Clozapine is also associated with 
increased mortality in elderly patients diagnosed with dementia-related psychosis. Clozapine 
induces weight gain with ≥ 7% during the first six months of the treatment due to disruption 
of the metabolism of patients - body gains increased energy from fat and not carbohydrates, 
resulting in high levels of the latter thus leading to insulin resistance and diabetes. When 
compared to FGAs, clozapine shows low incidence of EPSEs and does not show effects on 
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prolactin levels. All these side effects become more apparent when the dose of clozapine 
exceeds 450 mg/day.
66
 
2.4. Risperidone 
Risperidone (Figure 9) is an atypical (2
nd
 generation) antipsychotic which was approved in 
1993 for the treatment of schizophrenia,
72
 bipolar disorder, and irritability associated with 
autism. Risperidone is on the World Health Organisation’s list of essential medicines and is 
available as a generic medication.
35
 Risperidone combines the known antipsychotic effects of 
conventional D2 antagonist antipsychotics with the clozapine-like 5-HT antagonists. 
Risperidone is the first antipsychotic to have been granted approval for use on children 
between the ages of 13 and 17.
73
 
 
Figure 9.  Molecular structure of risperidone. 
2.4.1. Synthesis 
Risperidone, was developed in the late 1980s by Janssen Pharmaceuticals, a division of 
Johnson & Johnson. It is usually synthesised via condensation of separately prepared 3-(2-
chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,a]-pyrimidin-4-one with 6-fluoro-3-
(piperidin-4-yl)benzo[d]isoxazole in the presence of potassium iodide and sodium carbonate 
(Scheme 4).
74, 75
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Scheme 4.  Synthesis of risperidone from the main building blocks.  
The piperidine component is prepared by condensation of an acyl chloride with 1,3-
difluorobenzene in the presence of aluminium chloride followed by hydrolysis, formation of 
an oxime, and dehydrohalogenation to create the five-membered ring. Cyclocondensation 
between 2-aminopyridine and a derivative of butyrolactone results in the formation of a 
pyridopyrimidine derivative. Hydrogenation on Pd/C gives the tetrahydroxypyridopyrimidine 
whose alcohol group is substituted by a chlorine to give the desired second component. 
2.4.2. Mode of action and metabolism 
Risperidone has significant affinity for D2, 5-HT2A, 5-HT2C, H2, α1, and α2 receptors, and a 
lower affinity for D1, 5-HT1D, 5-HT1C, and 5-HT1A receptor subtypes.
76
 Risperidone occupies 
more D2 receptors than the 48% needed to achieve a clinical response at the recommended 
therapeutic dose (6 mg/day).
77
 This high affinity results in a long half-life.  
The action of risperidone on serotonin receptors (5-HT2A and 5-HT2C) is expected to be 
responsible for its lower extrapyramidal side effect liability.
78
 
Risperidone is mainly metabolised by alicyclic hydroxylation to give the enantiomeric 9-
hydroxyrisperidone which is also an antipsychotic agent.
79
 Its racemate, paliperidone, is 
commercially available for the treatment of schizophrenia as well.
80
 N-dealkylation can occur 
at the piperidine nitrogen. Most of the metabolised and non-metabolised risperidone is 
excreted in the urine.
81
 
2.4.3. Effectiveness 
Risperidone, based on the benzisoxazole skeleton, ameliorates both positive and negative 
symptoms of schizophrenia, based mainly on its potent serotonin 5-HT2A and dopamine D2 
receptor-blocking properties. Depending on studies, better therapeutic effects have been 
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observed either with risperidone or haloperidol in the treatment of negative symptoms of 
schizophrenia.
82
 However risperidone, as a 2
nd
-generation antipsychotic drug has lower 
extrapyramidal side effects compared to haloperidol (1
st
-generation antipsychotic drug). 
The effectiveness of risperidone has also been studied on children.
83, 84
 Symptoms of 
adolescent-onset psychosis are usually similar to those developed by adults and diagnosis is 
therefore performed using the same criteria. However some other symptoms such as the 
negative symptoms are more pronounced for children. Trials on adolescent population are 
sometimes conducted without placebo and therefore dose-response studies can be conducted. 
Higher efficacy was observed for higher doses of Risperidone.  
2.4.4. Limitations 
Commonly reported side effects of risperidone include agitation, akathisia, constipation, 
dizziness, drowsiness, dystonia, extrapyramidal reaction, nausea, rhinitis, and weight gain. 
Risperidone can be associated with higher levels of prolactin secretion than other 
antipsychotic drugs.
85
 These limitations have also been reported for children. Extrapyramidal 
symptoms are sometimes treated by benzatropine (Figure 10). 
 
Figure 10.  Molecular structure of benzatropine. 
Prolactin is secreted by the anterior pituitary. An elevation of prolactin inhibits the 
hypothalamic-pituitary axis, suppresses gonadotropin-releasing hormone release from the 
hypothalamus and also reduces estrogen and testosterone both in males and females. Modest 
elevations of prolactin are associated with amenorrhea, galactorrhea, hirsutism, decreased 
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libido, and hypogonadism for women; decreased libido and reduced spermatogenesis for 
men.
86
 
2.5.Quetiapine 
Quetiapine (Figure 11) is an atypical (or 2
nd
 generation) antipsychotic which is approved for 
the treatment of schizophrenia and some other illness (bipolar disorder, major depressive 
disorder). It is formulated as tablets and used to treat both positive and negative symptoms. 
Quetiapine was first approved by the FDA in 1997 for the treatment of schizophrenia.
87
 A 
sustained-release version was approved by the FDA in 2007 for use as maintenance treatment 
for schizophrenia in addition to acute treatment.
88
 Several generic versions are now available 
on the market. 
 
Figure 11.  Molecular structure of quetiapine. 
2.5.1. Synthesis 
Quetiapine is a tetracyclic compound which structure is close to those of clozapine and other 
tetracylic antipsychotics. AstraZeneca developed this compound from 1992. It belongs to the 
chemical class of dibenzothiazepine derivatives, with fumarate used for the formation of the 
salt. The synthesis was first described in a patent publication, starting from 
dibenzo[b,f][1,4]thiazepin-11-[10H]one which is first halogenated phosphorous oxychloride, 
then condensed with 1-(2-hydroxyethoxy)ethyl piperazine (Scheme 5).
89
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Scheme 5.  Synthesis of quetiapine, as reported in the initial patent.89 
Several other patents filed by the same company describe slightly different pathways to 
obtain quetiapine with different aims: generation of less hazardous waste, replacement of 
hazardous reagent by less hazardous ones, higher purity obtained, pathway involving a one-
pot process. The synthesis of the starting material has also been reported in the literature 
using different routes.
90
 Other patents describe the sustained release formulations of 
quetiapine using different polymers
91
 to either form gels
92
 or micro matrix particles.
93
 
2.5.2. Mode of action and metabolism 
Quetiapine is an antagonist at multiple neurotransmitter receptors in the brain: dopamine D1 
and D2, serotonin 5-HT1A and 5-HT2, histamine H1, and adrenergic α1 and α2 receptors.
94
  
The mechanism of action of quetiapine is not fully elucidated; however it has been proposed 
that its efficacy is mediated through a combination of D2 and 5-HT2 antagonism. Quetiapine 
has been shown to occupy around 30% of D2 receptors at therapeutic doses, which is lower 
than the 60-75% range associated with antipsychotic efficacy; such a low percentage can be 
explained by the fast dissociation from the D2 receptor.
95
 
Quetiapine is mainly eliminated via the hepatic metabolism with a mean terminal half-life of 
about six hours.
96
 Quetiapine is highly metabolised in the body as less than 1% of the 
administered dose is excreted as unchanged drug. The major metabolic pathways are 
sulfoxidations and oxidations, with both metabolites being pharmacologically inactive. 
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Another important metabolite is norquetiapine (N-desalkyl quetiapine, Figure 12) which is 
pharmaceutically active: it has a moderate affinity for the 5-HT2C receptor antagonist and is a 
partial agonist for the 5-HT1H receptor, which may be associated with cognitive and mood 
enhancing/stabilising properties.
96
  
 
Figure 12.  Molecular structure of norquetiapine. 
Quetiapine has low affinity for muscarinic receptors while norquetiapine acts as an antagonist 
at the M1, M3, and M5 muscarinic receptors. The side-effect profile of quetiapine may come 
from such interactions.
97
 
2.5.3. Effectiveness 
Quetiapine has been shown to be efficacious for patients diagnosed with schizophrenia across 
a broad range of symptoms including depression, anxiety, and hostility.
98
 The positive 
symptoms were also improved. Greater improvements were observed with patients receiving 
a slightly higher dose than the average dose of 300 mg/day. Quetiapine is generally well-
tolerated by patients. Studies have also been conducted by comparing quetiapine with other 
2
nd
 generation antipsychotic drugs, focusing on their differential neurocognitive 
effectiveness. The hypothesis that an increase in neurocognitive performance could be a 
reflection of psychotic symptoms was not confirmed however the authors stipulate that such a 
link exists,
99
 especially as a better response has been observed for patients taking quetiapine 
compared to conventional antipsychotics.
100
 Quetiapine does not induce extrapyramidal side 
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effects nor increase prolactin levels across the entire therapeutic range, similarly to 
clozapine.
99
 
2.5.4. Limitations 
Quetiapine has been associated with higher risk for somnolence, dizziness, asthenia, and dry 
mouth compared to conventional antipsychotics or risperidone. Constipation, tachycardia, 
orthostatic hypotension, dyspepsia, and weight gain have also been reported. Sporadically 
reported side-effects include syncopal episodes, leucopenias, neutropenias, and peripheral 
angioedema.
101
 
The extended-release formulation of quetiapine has been developed to allow a once-daily 
dosage regimen, hence improving the patient quality of life and ensuring medication is more 
likely to be taken as prescribed by physicians. However adverse effects were found to be 
significantly more likely compared with placebo or the immediate-release formulation.
102
  
2.6. Aripiprazole 
Aripiprazole (Figure 13) is an atypical antipsychotic drug which is approved worldwide for 
the treatment of adult patients diagnosed with schizophrenia. 
 
Figure 13.  Molecular structure of aripiprazole. 
It can be used both as an oral formulation for long-term treatment or as an intramuscular 
formulation (injection) for the control of acute agitation seen in schizophrenic patients. The 
oral formulation of the drug is effective in treating the positive and negative symptoms of 
schizophrenia.
103
 Aripiprazole was approved by the FDA for treatment of the disorder in 
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2002.
4
 It possesses a unique receptor binding profile as all other SGAs are dopamine-receptor 
antagonists and it exhibits partial agonist activity as well as antagonist activity.
103
 Therefore, 
it is considered to be a dopamine-serotonin system stabiliser which cannot be observed in the 
activity of any other antipsychotic drug.
104
 
The FDA has recently approved (late 2017) the first drug in the USA with a digital ingestion 
tracking system, with the active ingredient being aripiprazole. Such a device allows a 
recording on when the medication is taken. While the product is not intended to improve 
patient compliance with their treatment regimen, it is expected to be useful for some patients 
to be able to track ingestion of medications.
105
 
2.6.1. Synthesis 
Aripiprazole is a quinoline derivative. It was developed by Otsuka in Japan in the mid-
1990s.
106
 
 
Scheme 6.  Synthesis of aripiprazole. Adapted from reference107 
Aripiprazole is composed of three different fragments: phenylpiperazine, a four-carbon 
aliphatic chain, and a modified quinoline moiety (Scheme 6). Its synthesis is based on the 
reductive alkylation of amine, with the phenylpiperazine acting as the amine moiety. The 
four-carbon aliphatic chain can be added first on both remaining fragments.
107
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2.6.2. Mode of action and metabolism 
Aripiprazole is different from all others antipsychotics owing to its unique receptor binding 
profile. Multiple studies in vivo demonstrated that it acts as a partial agonist at dopamine D2 
and D3 receptors, and serotonin 5-HT1A receptors. It also exhibits antagonism activity at 5-
HT2A receptors.
103
 Therefore, where neurotransmitter levels are high, aripiprazole will act as 
an antagonist and where the levels are low it will function as an agonist, stabilising the 
dysregulated dopamine and serotonin systems.
103;104
 Treatment with aripiprazole results in a 
reduction of extracellular levels of dopamine in the frontal cortex and striatum, which is 
indicative of decreased release of dopamine in these brain regions.
104
 Aripiprazole displays 
only minor affinity for α2 adrenergic receptors, muscarinic cholinergic receptors and 
histamine H1 receptors which accounts for its ability not to cause sedation, weight gain, 
postural hypotension and cognitive impairment.
108
 
In addition to partial D2 agonism, it has been recently suggested that aripiprazole also 
displays functionally selective properties, which leads to a unique pharmacological profile for 
this drug.
109
 Functional selectivity (the ability of a drug to trigger different signalling 
pathways through a single receptor) has been shown to be of significant importance for the 
understanding of the mechanism of action of some anti-schizophrenia drugs.
110
 In 2006, 
Mailman and co-workers reported clear evidence that aripiprazole affects D2L signalling 
pathways in a differential way and therefore not only acts as a partial agonist but also as a 
functionally selective D2 ligand.
111
  
The recommended initial and target dose of aripiprazole (oral formulation) is between 10 to 
15 mg/day which is taken at once. The approved dose of intramuscular aripiprazole is 9.75 
mg single injection. When aripiprazole is administered orally, it is absorbed with peak plasma 
concentrations reached in three hours, resulting in 87% absolute bioavailability. It is 
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metabolised in the liver by CYP450 enzymes (mainly 3A4 and 2D6 enzymes), via NN-
dealkylation, hydroxylation or dehydrogenation.
103
 
2.6.3. Effectiveness 
The oral formulation of aripiprazole is known to be effective in both minimising the 
symptoms of the disorder and preventing the relapsing episodes in patients with chronic 
schizophrenia.
103
 Aripiprazole is less effective than olanzapine for controlling the symptoms 
of schizophrenia but aripiprazole demonstrated lower incidence of weight gain as compared 
to olanzapine and other SGAs.
108;112
 It is also associated with a lower incidence of EPSEs 
than haloperidol and a reduced risk of metabolic syndrome compared to olanzapine. Several 
pharmacoeconomic analyses demonstrated that aripiprazole can provide more cost-effective 
treatment than other antipsychotic agents.
103
 
2.6.4. Limitations 
Aripiprazole is associated with different adverse events but the most frequent side effect is 
insomnia, affecting 22 to 42% of the patients.
103
 Other adverse events include headache, 
anxiety, nausea and sedation.
4, 103 
All these are seen more often in patients taking aripiprazole 
than in patients on other antipsychotic drugs.
4
 
2.7. Lurasidone 
Lurasidone (Figure 14) is a recently developed atypical antipsychotic drug, first approved in 
2010 by the FDA, used for the treatment of schizophrenia in the USA, Puerto Rico and 
Canada.
113
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Figure 14.  Molecular structures of lurasidone, perospirone, and ziprasidone. 
Lurasidone is structurally related to ziprasidone and perospirone.
114
 It is proved to be 
effective for both positive and negative symptoms of the disorder, as well as the cognitive 
deficits and mood symptoms seen in schizophrenic patients.
115
 It shows high affinity for a 
range of receptors, resulting in its powerful antipsychotic activity as well as antidepressant-
like effects.
116
 Lurasidone is poorly soluble in water, which results in low bioavailability. 
Therefore, lurasidone is administered with food which complicates the treatment and leads to 
poor effectiveness among patients diagnosed with schizophrenia. The formulation of 
lurasidone has been explored in the last years to overcome such issues; the use of 
nanosuspensions has been shown to enhance its bioavailability.
117;118 
2.7.1. Mode of action and metabolism 
Lurasidone acts as a full antagonist at dopamine D2 and serotonin 5-HT2A receptors.
116
 It is 
also a partial agonist at serotonin 5-HT1A which helps stabilizing the frontal cortex function. 
Stimulation of the 5-HT1A receptors reduces EPSEs such as epilepsy, dystonia and 
dyskinesia, which are all a result of the full blockage of dopamine D2 receptors. Lurasidone 
demonstrates high affinity for serotonin 5-HT7 receptors unlike other atypical antipsychotic 
drugs. The great effect of 5-HT7 antagonism on cognitive deficits, mood symptoms and 
memory problems associated with schizophrenia was demonstrated.
114
 Lurasidone shows low 
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affinity for 5-HT2C receptors which accounts for its low ability to cause weight gain. As for 
the adrenergic receptors, lurasidone demonstrates high affinity for α2C receptors (thus 
improving cognitive function) but low affinity for α1 and α2A receptors.
116
 It has minimal 
effect on histamine H1 and muscarinic M1 receptors but antagonism of these receptors is 
associated with weight gain, sedation and unfavourable cognitive effects.
114
 
The recommended dose of lurasidone is 40 to 120 mg/day which is administered once daily 
with food that contains at least 350 calories.
113
 After absorption, lurasidone is distributed in 
tissues, followed by rapid penetration in the CNS showing approximately 80% occupancy of 
dopamine D2 receptors. It is metabolised in the liver by CYP450 enzymes, mainly through 
CYP3A4 pathway. This process includes N-dealkylation, hydroxylation, S-oxidation, 
reductive cleavage, S-methylation, followed by a combination of some or all of these 
reactions. The active metabolites of lurasidone are shown in Scheme 7 and these possess 
pharmacological activity, contributing to the antipsychotic action of the main drug.
114
 
 
Scheme 7.  The active metabolites of lurasidone. BITP = 1-(1,2-benzisothiazol-3-yl)-
piperazine (adapted from reference
114
). 
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BITP (ID-11614) is one of the active metabolites of lurasidone and it is similar to perospirone 
and ziprasidone. In vivo studies show that BITP possesses some of the pharmacodynamic 
properties of lurasidone in rodent and non-rodent species.
114
 Both hydroxy-derivatives of 
lurasidone (ID-14326 and ID-14283) demonstrate similar binding profiles to the main drug – 
affinity for dopamine D2 and serotonin 5-HT2A, 5-HT1A and 5-HT7 receptors. After 
lurasidone is being metabolised it is excreted as 80% in faeces and 9% in urine.
114
 
2.7.2. Effectiveness and limitations 
Lurasidone can be used for both short and long term treatment of schizophrenia.
113
 Short term 
clinical trials show that lurasidone is effective in acute schizophrenia.
114
 Its pharmacological 
properties to improve cognitive processes and help with anxiety and depression for patients 
diagnosed with schizophrenia.
113;114
 One of the greatest advantages of lurasidone is thought to 
be its low potential to cause weight gain and metabolic disorders.
115
 
Lurasidone is associated with different adverse events including nausea, vomiting, insomnia, 
dizziness, sedation and somnolence.
113;114
 Doses above 80 mg/day are associated with 
akathisia (psychomotor restlessness).
115
 Lurasidone is shown to increase prolactin levels but 
to a lesser degree than other antipsychotic agents such as risperidone and paliperidone.
115
 The 
major disadvantage of lurasidone hydrochloride is its low solubility and bioavailability when 
administered orally without food (only 9 to 19% is being absorbed).
117
 Therefore, the 
recommendation for lurasidone is to be taken with food with at least 350 calories and no fat. 
This results in two-fold increase of the absorption rate of lurasidone. Such treatment 
compliance has been reported to be quite poor, hence the formulation of lurasidone has 
recently been studied to solve this issue. Lu et al. and Yu et al. demonstrated preparation of 
nanosuspensions by antisolvent precipitation-ultrasonication method and used these to 
enhance the dissolution and bioavailability of lurasidone.
117
 An increased dissolution rate, 
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rapid absorption and enhanced oral bioavailability were reported for the nanosuspension 
compared to the original formula.
117;118 
2.8. Summary 
It is clear that the activity profile on receptors of clinically-approved drugs is directly related 
to their biological mechanisms of action. A number of studies have unambiguously 
demonstrated the binding of these agents to various receptors (therefore shining light on their 
respective modes of action), whilst recent studies are still suggesting involvement of other 
receptors. The complexity of the interactions makes a comprehensive overview of clinically-
approved drugs interactions with receptors difficult, but Table 3 summarises the main activity 
profiles of such drugs (when activity is written in bold, the drug acts as a full antagonist or 
agonist; otherwise the action is either partial or the affinity is relatively weak), along with 
chosen examples of recently reported studies.   
Table 3. Summary of the activity profile on receptors of clinically-approved drugs discussed in 
section 1. 
Drug 
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st
 1
st
 2
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 2
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 2
nd
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  2
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Dopamine 
D1 Antag
119
 Antag
57
 Antag
68
 Antag
120
 Antag
94
 
Ag + 
Antag
121
 
- 
D2 Antag
122
 Antag
52
 Antag
66
 Antag
123
 Antag
95
 
Ag + 
Antag
109, 
111
 
Antag
124
 
D3 Antag
125
 
Inv 
Ag
57;58
 
Antag
68
 Antag
126
 Antag
127
 
Ag + 
Antag
103
 
- 
D4 Antag
128
 - Antag
68
 Antag
129
 Antag
127
 - - 
D5 - - - Antag
78
 Antag
127
 - - 
Serotonin 5-HT1 Antag
130
 Ag
52
 Antag
65
 Antag
78
 
Ag + 
Antag
131
 
Ag + 
Antag
103
 
Antag
116
 
40 
 
5-HT2 Antag
38
 Antag
52
 Antag
65
 Antag
78
 Antag
131
 
Ag + 
Antag
103
 
Antag
116
 
5-HT7 - - - - - Antag
103
 Antag
114
 
α-adregenic 
α1 Antag
132
 Antag
52
 Antag
68
 Antag
133
 Antag
134
 Antag
108
 - 
α 2 Antag
135
 Antag
52
 Antag
68
 Antag
133
 Antag
134
 Antag
108
 Antag
116
 
Histamine 
H1 Antag
136
 - Antag
68
 Antag
137
 - Antag
108
 Antag
114
 
H2 Antag
136
 - - Antag
137
 - - - 
H3 Antag
138
 - - - - - - 
Muscarinic 
acetylcholine 
M1 Antag
139
 - Antag
68
 - - - - 
M2 Antag
139
 - Antag
68
 - - - - 
NMDA   Antag
140
 Antag
59
 Antag
70
 - - - - 
Ag: Agonist; Antag: Antagonist; Inv Ag: Inverse agonist. 
3. Emerging Approaches for the Treatment of Schizophrenia 
3.1. Modulation of Glutamatergic Signalling 
First- and second-generation antipsychotic agents have a profound effect on dopaminergic 
and serotonergic systems and therefore target positive symptoms of schizophrenia, and to a 
small extend negative symptoms and cognitive deficits. Schizophrenia includes complex 
alterations in the neurochemistry of key brain regions which are associated with cognition, 
neurodevelopment, memory, sensory processing and emotions. Dopamine and serotonin play 
a key role in the modulation of these brain regions but glutamate and GABA, which are the 
main excitatory and inhibitory transmitters, do regulate the signalling through these 
circuits.
141
 Therefore, a new approach for the treatment of schizophrenia is to increase the 
activity of some glutamate receptors (such as NMDA receptors, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors and metabotropic glutamate (mGlu) 
receptors) so as to restore the signalling in the glutamatergic systems. Agents regulating the 
glutamatergic neurotransmission are reported to minimise all three groups of symptoms 
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associated with schizophrenia and could therefore provide a solution in the treatment of this 
illness.
141
 
3.1.1. Glycine Transporter 1 (GlyT1) Inhibitors 
The NMDA receptor is one of the glutamate receptors which is known to be involved in the 
mechanism of schizophrenia.
141;142
 Studies have demonstrated a reduction in the function of 
the NMDA receptor in patients diagnosed with schizophrenia; therefore efforts are targeted 
towards enhancing the glutamatergic signalling.
16
 Selective antagonists at the NMDA 
receptor have shown to induce positive, negative, and cognitive symptoms similar to those 
seen in patients diagnosed with the disorder.
141;142
 Furthermore, agents such as glycine and 
serine have been shown to increase NMDA receptor responses to glutamate and thus to 
stabilise the dysregulated glutamatergic systems.
143
 Glycine is a co-agonist for the activation 
of the NMDA receptor by glutamate and so increasing the synaptic glycine levels could 
improve the NMDA receptor function and enhance the glutamate neurotransmission.
144
 
Direct administration of glycine was a promising approach as this amino acid demonstrated a 
positive effect on the symptoms related to schizophrenia. However, glycine is not a suitable 
therapeutic agent as it is associated with a few serious limitations, including poor 
pharmacokinetic profile, low brain exposure.
141
 The clearance of glycine is regulated by the 
GlyT1 and since glycine itself cannot be used as an agent for the treatment of schizophrenia, 
highly selective GlyT1 inhibitors have been developed to increase the concentration of 
glycine in the glutamatergic systems and facilitate NMDA receptor responses to 
glutamate.
141;142
 One of the first GlyT1 inhibitors was structurally related to sarcosine which 
is an endogenous GlyT1 inhibitor.
141
 These agents have shown efficacy in minimising the 
symptoms of schizophrenia but were also associated with serious adverse events such as 
compulsive walking, respiratory distress and in some occasions death.
145;146
 Recent studies 
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have focused on GlyT1 inhibitors which are structurally distinct from sarcosine. RG1678 
(Figure 15) is the first potent and selective GlyT1 inhibitor, developed by Roche.
147
  
 
Figure 15.  Molecular structure of RG1678. 
A phase II clinical study demonstrated efficacy on the negative symptoms observed among 
patients diagnosed with schizophrenia when administered as an add-on treatment to atypical 
drugs.
148
 In 2014, Roche has also designed a novel structural class of GlyT1 inhibitors – 3-
amido-3-aryl-piperidines.
149
 One of these compounds (Figure 16) demonstrated high GlyT1 
potency and excellent brain penetration in animal models which resulted in its efficacy at 
very low plasma concentrations.
149
 
 
Figure 16.  Molecular structure of (R)-2-methoxy-N-(1-methyl-3-phenylpiperidin-3-yl)-6-
(methylthio)-4-(trifluoromethyl)benzamide. 
ASP2535 (Figure 17) is another GlyT1 inhibitor identified by Harada et al. which is shown to 
be effective for the treatment of cognitive deficits in animal models of schizophrenia and 
Alzheimer’s disease.150  
 
43 
 
Figure 17.  Molecular structure of ASP2535. 
Its pharmacological profile indicates that it is an orally active, rapidly absorbed and blood-
brain-barrier penetrable GlyT1 inhibitor.
150
 
3.1.2. mGluR Positive Allosteric Modulators (PAMs) 
Metabotropic glutamate receptors are G-protein coupled glutamate receptors which are 
thought to be involved in the mechanism of schizophrenia as they take part in modulating 
NMDA receptor-mediated neurotransmission.
142
 Metabotropic glutamate receptor subtype 5 
(mGluR5) is of interest as it is known to be related to the NMDA receptor and more 
specifically, to physically interact with the NMDA receptor via binding to scaffolding 
proteins and also to potentiate NMDA receptor currents.
141
 mGluR5 PAMs have recently 
been developed and they act as modulators as they do not activate the receptor directly but 
they bind at an allosteric site and potentiate the responses to glutamate.
151
 Janssen and the 
Vanderbilt Center for Neuroscience Drug Discovery discovered a potent, selective and orally 
bioavailable mGluR5 PAM - VU0409551/JNJ-46778212 (Figure 18).
152
 
  
Figure 18.  Molecular structure of VU0409551/JNJ-46778212. 
VU0409551/JNJ-46778212 demonstrates an antipsychotic activity and cognition-enhancing 
efficacy without directly potentiating the NMDA receptor modulation.
152
 
Recently, Yang et al. reported the robust in vivo efficacy in preclinical model of 
schizophrenia of BMS-955829 (Figure 19), a mGluR5 PAM having the potential to treat 
cognitive abnormalities seen among patients.
153
 It displays high functional PAM potency, 
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high selectivity for the mGluR5 subtype, excellent mGluR5 binding affinity and low glutamate 
fold shift.
153
 
 
Figure 19.  Molecular structure of BMS-955829. 
3.1.3. AMPA Receptor PAMs 
AMPA receptors are non-NMDA-type ionotropic glutamate receptors which mediate the 
majority of fast amino acid neurotransmission and are involved in the expression of long-
term potentiation (LTP), a phenomenon associated with learning and memory.
154;155
 AMPA 
receptors are also responsible for the fast excitatory postsynaptic potentials (EPSPs) and have 
recently been of high interest as glutamatergic neurotransmission could be regulated by 
activating this type of glutamate receptors.
142
 Direct AMPA receptor agonists may cause 
severe neurotoxicity owing to their ability to interact with the glutamate receptor binding site 
and could therefore overstimulate the receptors. AMPA receptor PAMs (also known as 
potentiators) have no effect without the presence of the natural ligand at the synapse and 
therefore apply finer tuning and enhance the glutamatergic neurotransmission without 
causing excitotoxic effects.
154;155
 AMPA receptor PAMs act by slowing the rate of key 
functional AMPA receptor properties such as desensitisation and deactivation.
154;155
 
Desensitisation is the process of ion channel closure with glutamate still bound to the 
receptor. Deactivation is the process of ion channel inactivation following the dissociation of 
the agonist.
154;155
 Therefore, AMPA receptor PAMs can regulate the amplitude and duration 
of glutamate-stimulated EPSPs.
154
 Recently, AMPA receptor potentiators have been used to 
enhance the glutamatergic neurotransmission, improve cognitive deficits and help with 
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various neurological disorders such as schizophrenia, depression and Parkinson’s disease. 
Francotte et al. reported the synthesis of a benzothiadiazine dioxide compound (7-chloro-4-
cyclopropyl-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide) (Figure 20). This 
compound is an AMPA receptor PAM which demonstrated favourable physiochemical 
properties and low in vivo acute toxicity observed in animal models.
155
 
 
Figure 20.  Molecular structure of 7-chloro-4-cyclopropyl-3,4-dihydro-2H-
benzo[e][1,2,4]thiadiazine 1,1-dioxide. 
By measuring the cerebral and plasma concentrations after oral administration in animal 
models (3 mg/kg), benzothiadiazine dioxide was confirmed to be easily distributed into the 
brain. Carrying out an ex vivo electrophysiological test performed on rat hippocampal slices, 
it has been shown that the compound interacts with the postsynaptic AMPA receptors located 
on hippocampal neurons. Electrophysiological recordings of the postsynaptic response in the 
hippocampus in animal models demonstrated the in vitro effects of the benzothiadiazine 
dioxide on EPSPs on hippocampal slices, as well as its ability to increase the induction and 
the maintenance of LTP. As a result, this compound was found to considerably improve 
cognition processes at doses as low as 1 mg/kg.
155
 
Citti et al. identified 7-chloro-5-(furan-3-yl)-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-
dioxide which is the unsaturated derivative of 7-chloro-5-(furan-3-yl)-3-methyl-3,4-dihydro-
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (AMPA receptor PAM) when the latter is 
metabolised by hepatic CYP450 enzymes (Figure 21).
156
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Figure 21.  Molecular structures of the parent compound and its metabolite. 
Animal microdialysis studies demonstrated that the metabolite is able to cross the blood-brain 
barrier, increasing the acetylcholine and serotonin levels in the hippocampus. Experimental 
data confirmed that the metabolite has the same pharmacological activity as its parent 
compound but it also displays enhanced chemical and stereochemical stability, as well as an 
enriched pharmacokinetic profile when compared to the parent compound.
156
 
Recently, Ward et al. reported the synthesis of UoS12258 (Figure 22), a selective AMPA 
receptor PAM which has an excellent in vivo efficacy profile.
157
 
 
Figure 22.  Molecular structure of UoS12258. 
UoS12258 demonstrated an equivalent potency for all AMPA receptor subtypes and no 
measurable activity for other glutamate receptors. It has also been shown to enhance the 
AMPA receptor-mediated activity in vivo at low doses as well as to improve learning and 
memory processes in animal models when administered at higher doses. Preclinical studies 
confirmed that UoS12258 is expected to be a highly effective agent for treating the cognitive 
deficits seen among schizophrenic patients.
157
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3.2. Selective Agonists of alpha7 nicotinic acetylcholine receptor (α7 nAChR) 
Neuronal nAChRs are ligand-gated ion channels permeable to cations such as Na
+
, K
+ 
and 
Ca
2+
.
158
 nAChRs are spread in both the peripheral nervous system (PNS) and the CNS
158
 and 
their function is to alter synaptic plasticity and to influence cell excitability and the release of 
other neurotransmitters such as dopamine, serotonin, glutamate and GABA.
159;160
 These 
nAChRs are regulated by the endogenous agonist acetylcholine (ACh)
159
 and are known to be 
related to cognitive and attentional processing.
160
 Numerous nAChRs are known but α7 
nAChR, which is one of the most commonly expressed subtypes of nicotinic receptors,
159
 is 
of particular interest due to its role in reducing the cognitive deficits associated with 
schizophrenia. The homopentameric α7 nAChR consists of five α7 subunits and all of them 
provide an orthosteric binding site for the endogenous ligand ACh.
161
 α7 nAChRs are located 
in the cerebral cortex, hippocampus and subcortical limbic regions and these receptors are 
associated with memory, sensory gating and neuronal plasticity.
162
 Since α7 nAChRs have 
implications in the regulation of cognitive processes such as memory and attention, novel α7 
nAChR agonists have been designed in order to improve the cognitive performance of 
patients diagnosed with different neurological disorders such as schizophrenia, Alzheimer’s 
disease, depression and attention deficit hyperactivity disorder.
158
 Abnormalities of α7 
nAChRs function leads to deficits in sensory gating in patients diagnosed with schizophrenia 
and reduced expression of nAChRs in the hippocampus, reticular nucleus of the thalamus, 
dentate gyrus and frontal cortex of subjects diagnosed with the disorder.
160
  
Nicotine has been shown to have a positive impact on attentional processing and cognitive 
functions in animal models, healthy volunteers and subjects diagnosed with schizophrenia.
163
 
Acute administration of nicotine has been found to enhance cognitive performance in 
schizophrenic patients and since nicotine acts as an agonist at nAChRs, this has linked 
nicotinic receptors to schizophrenia.
158;160
 As a result, α7 nAChR agonists are currently 
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explored as novel agents to treat cognitive dysfunction seen in patients diagnosed with mental 
disorders such as schizophrenia. 
O’Donnell et al. developed CP-810123 (Figure 23) as a potential agent for the treatment of 
cognitive deficits associated with neurological conditions including schizophrenia and 
Alzheimer’s disease.164 
 
Figure 23.  Molecular structure of CP-810123. 
CP-810123 is a potent and selective α7 nAChR agonist with excellent pharmaceutical 
properties. In animal models, it demonstrated high oral bioavailability and good brain 
penetration which results in high levels of receptor occupancy. It has shown acceptable 
cardiovascular safety profile and genetic toxicology profile, as well as in vivo efficacy in 
auditory sensory gating and novel object recognition (NOR) models which are both indicative 
of improved cognitive function.
164
 
Zanaletti et al. identified the compound SEN78702,WYE-308775 (Figure 24) as a potent and 
selective full agonist of the α7 nAChR.165 
 
Figure 24.  Molecular structure of SEN78702,WYE-308775 
This α7 nAChR full agonist displayed rapid absorption, excellent bioavailability, good 
selectivity profile and moderate clearance. In a prepulse animal model, SEN78702, WYE-
308775 demonstrated the ability to decrease pharmacologically induced deficits through the 
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glutamatergic system. It has also been subject to preliminary toxicology assessment and it 
indicated low toxicity risk.
165
 
Recently, King et al. reported the synthesis of BMS-933043 (Figure 25) as a novel and potent 
α7 nAChR partial agonist.166 
 
Figure 25.  Molecular structure of BMS-933043 
BMS-933043 demonstrated high selectivity for the α7 nAChR and against other nAChR 
subtypes, as well as against the 5-HT3A receptor. Its effect on episodic memory was assessed 
in the animal NOR model where it displayed a robust increase in novel object exploration at 
doses of 0.1 – 10 mg/kg which is indicative of enhanced object recognition memory.166 
Bristow et al. reported the potent binding affinity of BMS-933043 to native animal and 
recombinant human α7 nAChRs and no agonist or antagonist activity at other nAChR 
subtypes.
167
 It has been shown to considerably improve cognition and sensory processing in 
preclinical models of schizophrenia and it has also displayed favourable preclinical safety 
profile.
167
 As a result of its favourable preclinical profile, BMS-933043 has been selected for 
further development to support clinical evaluation in humans.
167
 
Hill et al. reported the synthesis of a series of quinuclidine-containing spiroimidates and their 
function as α7 nAChR partial agonists. Two of them – (1′S,3′R,4′S)-N-(7-bromopyrrolo[2,1-
f][1,2,4]triazin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octan]-2-amine and 
(1′S,3′R,4′S)-N-(7-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-
bicyclo[2.2.2]octan]-2-amine (Figure 26) were identified as potent and selective α7 nAChR 
partial agonists.
168
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Figure 26.  Molecular structures of the two quinuclidine-containing spiroimidate 
compounds developed by Hill et al. 
In animal models, these two partial α7 nAChR agonists demonstrated an ability to enhance 
learning and memory function, to reverse memory and sensory gating deficits and also to 
reduce anxiety.
168
 
Conclusions 
Schizophrenia is a complex and unpredictable mental disorder which affects several domains 
of cognition and behaviour. It is a heterogeneous illness characterised by positive, negative, 
and cognitive symptoms, often accompanied by signs of depression. The disorder follows a 
complex route combining different anatomical changes in the brains of schizophrenic 
patients, as well as alterations of receptors and abnormalities in the concentrations of various 
neurotransmitters. Schizophrenia cannot be cured but suitable medications called 
‘antipsychotic drugs’ are available to help with its severe symptoms. Second-generation 
atypical antipsychotic drugs are the current choice for most of the patients and these show 
different properties, receptor binding profiles, pharmacological features and adverse events. 
Here, we have tried to provide some basic information on the neurobiology and 
neurochemistry of schizophrenia, and surveyed the synthesis, mode of actions, and 
limitations of the different clinically antipsychotic agents used since the 1950s. It is however 
clear that the development of new molecules is crucially needed to overcome the major 
limitations of currently used drugs. A number of clinical trials are currently undergoing, and 
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we highlighted some of the most recent strategies used for the design of drugs that will 
achieve both efficiency and low level of side effects, in particular via modulation of 
glutamatergic signalling and selective agonists of α7 nAChR receptors.  
Abbreviations 
1
H-MRS proton magnetic resonance spectroscopy 
5-HT serotonin 
Ach acetylcholine 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BITP 1-(1,2-benzisothiazol-3-yl)-piperazine 
CNS central nervous system 
CPZ chlorpromazine 
CYP450 cytochrome P450 
DLPFC dorsolateral prefrontal cortex 
DTI diffusion tension imaging 
EPSEs extrapyramidal side effects 
EPSP excitatory postsynaptic potential 
FBCs full blood counts 
FDA Food and Drug Administration 
FGA first-generation antipsychotics 
GABA γ-aminobutyric acid 
GLX glutamate and glutamine 
GlyT1 glycine transporter 1 
LTP long-term potentiation 
mGlu metabotropic glutamate 
mGluR5 metabotropic glutamate receptor subtype 5 
MRI magnetic resonance imaging 
nAChR nicotinic acetylcholine receptor 
NMDA N-methyl-D-aspartic acid 
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NOR novel object recognition 
PAM positive allosteric modulator 
PET positron emission tomography 
PFC prefrontal cortex 
PNS peripheral nervous system 
SGA second-generation antipsychotics 
SPECT single-photon emission computed tomography 
STG superior temporal gyrus 
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